Article

Case Study of a 33-Year-Old With Metastatic Colorectal Cancer

Author(s):

In this segment, David Liu, shares a case study of a 33-year-old woman with stage 4 colorectal cancer that had metastasized to the liver.

In this segment, David Liu, shares a case study of a 33-year-old woman with stage 4 colorectal cancer that had metastasized to the liver. The patient presented to Liu's practice with the primary tumor intact and bowel obstruction. Following resection of the primary tumor, systemic therapy was initiated with cetuximab plus FOLFOX chemotherapy for two months before toxicity was encountered. At this time, it was discovered that the patient had a KRAS mutation, which limited her subsequent therapeutic options.

Upon review by a tumor board, the decision was made to treat her with liver-directed SIR-Spheres (Yttrium-90-resin microspheres) off protocol. Liu and his colleagues made this decision after a careful consideration of the patient’s presentation of disease, nonresponse and intolerance to previous systemic therapy, KRAS-mutant status and her estimated survival of approximately one year.

After her selective internal radiation therapy (SIRT) procedure, the liver was not a consideration anymore, since subsequent scans continued to show a lack of liver lesions, says Liu. By treating the liver, the patients had an improved chance of living longer. The patient later developed ovarian drop metastases (Krukenberg tumor), which was surgically resected. She also developed pulmonary lesions, which were effectively treated with a combination of ablation and surgical resection. In the end, she developed brain metastases.

The patient survived 54 months, which is significantly longer than the 12-month anticipation, according to Liu.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Related Content